source
- RevMed's pancreatic cancer drug Rasonque generates $198M in Q3, far exceeding forecastsRevMed reported $198 million in revenue from its newly launched pancreatic cancer therapy Rasonque during the third quarter, roughly ten times the $19 million estimate from Truist Securities. The…
- AstraZeneca reportedly bids $10 billion for metabolic biotech Rhythm PharmaceuticalsAstraZeneca is said to have made a $10 billion offer to acquire Rhythm Pharmaceuticals, a biotech that develops treatments for rare neuroendocrine disorders. The proposal values Rhythm at $124 per…